Moderna will construct a state-of-the-art manufacturing facility in Canada in order to provide direct access to mRNA vaccines for the Covid-19 pandemic, as well as future viral threats and respiratory viruses.
Moderna Chief Executive Officer Stéphane Bancel sees significant growth opportunities for his company and messenger RNA-based vaccines.
Valneva SE was awarded Breakthrough Therapy Designation for the company’s single-shot chikungunya vaccine candidate, VLA1553, by the U.S. Food and Drug Administration.
After months of bad news regarding Covid-19 vaccine manufacturing issues, Emergent BioSolutions posted positive two-year data related to the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate.
Three scientists will share the Nobel Prize for Medicine for their seminal discoveries that led to the identification of the Hepatitis C virus, a significant health problem across the globe that can lead to cirrhosis and liver cancer in patients.
BiospaceBioSpace reviews some recently published scientific studies, including researchers with the University of Colorado Anschutz Medical Campus releasing a new study calling attention to the emergence of mosquito-borne viral outbreaks in West Africa.
Roche’s influenza treatment Xofluza – a one-dose pill that can clear flu symptoms within days – may cause a mutation of the virus that leads to drug resistance, researchers reported.
French drugs and healthcare group Sanofi signed a rights deal with Roche for Tamiflu in the United States.
Roche said the Swiss drugmaker’s new one-dose flu medicine Xofluza was comparable to the company’s 20-year-old drug Tamiflu in reducing the duration of symptoms of the viral disease, citing a study of the drug in children aged one to 12 years old.
